Creditors call for Protein Sciences liquidation

Two weeks after Protein Sciences announced that it had begun producing the world's first swine flu vaccine, creditors of the company filed a petition for involuntary bankruptcy. The creditors claimed $11.7 million. Emergent BioSolutions struck a deal last May to buy Protein Sciences' assets for $28 million in cash and the assumption of a $20 million note. Report

Suggested Articles

Pfizer’s 2017 spin-out company SpringWorks has lost president and founder Lara Sullivan, M.D. who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.

In our EuroBiotech roundup this week, Pfizer Ventures backs ImmunOs, Genmab shares cancer data and Newron delays readout.